Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

SBC vs SSKN vs SKIN vs INMD

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SBC
SBC Medical Group Holdings Incorporated

Consulting Services

IndustrialsNASDAQ • US
Market Cap$329M
5Y Perf.-68.0%
SSKN
STRATA Skin Sciences, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$7M
5Y Perf.-98.0%
SKIN
The Beauty Health Company

Household & Personal Products

Consumer DefensiveNASDAQ • US
Market Cap$118M
5Y Perf.-92.3%
INMD
InMode Ltd.

Medical - Devices

HealthcareNASDAQ • IL
Market Cap$882M
5Y Perf.-52.2%

SBC vs SSKN vs SKIN vs INMD — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SBC logoSBC
SSKN logoSSKN
SKIN logoSKIN
INMD logoINMD
IndustryConsulting ServicesMedical - DevicesHousehold & Personal ProductsMedical - Devices
Market Cap$329M$7M$118M$882M
Revenue (TTM)$178M$31M$296M$375M
Net Income (TTM)$43M$-11M$-6M$87M
Gross Margin73.7%57.8%64.9%77.8%
Operating Margin33.3%-33.3%-3.6%21.3%
Forward P/E7.1x9.6x
Total Debt$12M$16M$379M$13M
Cash & Equiv.$125M$7M$233M$303M

SBC vs SSKN vs SKIN vs INMDLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SBC
SSKN
SKIN
INMD
StockSep 22May 26Return
SBC Medical Group H… (SBC)10032.0-68.0%
STRATA Skin Science… (SSKN)1002.0-98.0%
The Beauty Health C… (SKIN)1007.7-92.3%
InMode Ltd. (INMD)10047.8-52.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: SBC vs SSKN vs SKIN vs INMD

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: SBC leads in 6 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
SBC
SBC Medical Group Holdings Incorporated
The Income Pick

SBC carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • beta 0.76
  • Lower volatility, beta 0.76, Low D/E 6.3%, current ratio 3.01x
  • Beta 0.76, current ratio 3.01x
  • 6.1% revenue growth vs SKIN's -10.0%
Best for: income & stability and sleep-well-at-night
SSKN
STRATA Skin Sciences, Inc.
The Growth Play

SSKN is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 0.6%, EPS growth 16.1%, 3Y rev CAGR 3.8%
Best for: growth exposure
SKIN
The Beauty Health Company
The Quality Angle

SKIN plays a supporting role in this comparison — it may shine differently against other peers.

Best for: consumer defensive exposure
INMD
InMode Ltd.
The Long-Run Compounder

INMD is the clearest fit if your priority is long-term compounding.

  • 105.0% 10Y total return vs SBC's -67.8%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthSBC logoSBC6.1% revenue growth vs SKIN's -10.0%
ValueSBC logoSBCLower P/E (7.1x vs 9.6x)
Quality / MarginsSBC logoSBC24.3% margin vs SSKN's -35.6%
Stability / SafetySBC logoSBCBeta 0.76 vs SKIN's 2.00, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)SBC logoSBC+0.3% vs SSKN's -93.3%
Efficiency (ROA)SBC logoSBC13.5% ROA vs SSKN's -35.9%, ROIC 72.3% vs -38.9%

SBC vs SSKN vs SKIN vs INMD — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SBCSBC Medical Group Holdings Incorporated

Segment breakdown not available.

SSKNSTRATA Skin Sciences, Inc.
FY 2024
Dermatology Recurring Procedures
63.1%$21M
Dermatology Procedures Equipment
36.9%$12M
SKINThe Beauty Health Company
FY 2025
Consumables
70.7%$213M
Delivery Systems
29.3%$88M
INMDInMode Ltd.
FY 2025
Capital Equipment
100.0%$289M

SBC vs SSKN vs SKIN vs INMD — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSBCLAGGINGSKIN

Income & Cash Flow (Last 12 Months)

Evenly matched — SBC and INMD each lead in 3 of 6 comparable metrics.

INMD is the larger business by revenue, generating $375M annually — 12.1x SSKN's $31M. SBC is the more profitable business, keeping 24.3% of every revenue dollar as net income compared to SSKN's -35.6%. On growth, INMD holds the edge at +5.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSBC logoSBCSBC Medical Group…SSKN logoSSKNSTRATA Skin Scien…SKIN logoSKINThe Beauty Health…INMD logoINMDInMode Ltd.
RevenueTrailing 12 months$178M$31M$296M$375M
EBITDAEarnings before interest/tax$62M-$5M$9M$81M
Net IncomeAfter-tax profit$43M-$11M-$6M$87M
Free Cash FlowCash after capex-$37M-$4M$29M$91M
Gross MarginGross profit ÷ Revenue+73.7%+57.8%+64.9%+77.8%
Operating MarginEBIT ÷ Revenue+33.3%-33.3%-3.6%+21.3%
Net MarginNet income ÷ Revenue+24.3%-35.6%-2.0%+23.3%
FCF MarginFCF ÷ Revenue-20.5%-11.3%+9.8%+24.2%
Rev. Growth (YoY)Latest quarter vs prior year-18.3%-21.2%-6.7%+5.3%
EPS Growth (YoY)Latest quarter vs prior year+3.2%-5.9%+38.0%-30.8%
Evenly matched — SBC and INMD each lead in 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — SBC and SKIN each lead in 2 of 6 comparable metrics.

At 6.7x trailing earnings, SBC trades at a 32% valuation discount to INMD's 9.7x P/E. On an enterprise value basis, SBC's 2.9x EV/EBITDA is more attractive than SKIN's 7331.2x.

MetricSBC logoSBCSBC Medical Group…SSKN logoSSKNSTRATA Skin Scien…SKIN logoSKINThe Beauty Health…INMD logoINMDInMode Ltd.
Market CapShares × price$329M$7M$118M$882M
Enterprise ValueMkt cap + debt − cash$216M$16M$264M$593M
Trailing P/EPrice ÷ TTM EPS6.65x-0.67x-5.69x9.73x
Forward P/EPrice ÷ next-FY EPS est.7.07x9.64x
PEG RatioP/E ÷ EPS growth rate0.98x
EV / EBITDAEnterprise value multiple2.92x7331.15x6.88x
Price / SalesMarket cap ÷ Revenue1.60x0.20x0.39x2.38x
Price / BookPrice ÷ Book value/share1.59x1.34x2.02x1.33x
Price / FCFMarket cap ÷ FCF19.17x3.17x10.46x
Evenly matched — SBC and SKIN each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

SBC leads this category, winning 7 of 9 comparable metrics.

SBC delivers a 17.5% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-8 for SSKN. INMD carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SBC scores 7/9 vs INMD's 3/9, reflecting strong financial health.

MetricSBC logoSBCSBC Medical Group…SSKN logoSSKNSTRATA Skin Scien…SKIN logoSKINThe Beauty Health…INMD logoINMDInMode Ltd.
ROE (TTM)Return on equity+17.5%-8.4%-9.4%+13.3%
ROA (TTM)Return on assets+13.5%-35.9%-1.2%+11.8%
ROICReturn on invested capital+72.3%-38.9%-6.8%+13.5%
ROCEReturn on capital employed+37.9%-36.0%-4.5%+12.1%
Piotroski ScoreFundamental quality 0–97473
Debt / EquityFinancial leverage0.06x3.31x6.20x0.02x
Net DebtTotal debt minus cash-$113M$9M$146M-$289M
Cash & Equiv.Liquid assets$125M$7M$233M$303M
Total DebtShort + long-term debt$12M$16M$379M$13M
Interest CoverageEBIT ÷ Interest expense596.05x-4.63x0.81x
SBC leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

INMD leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in INMD five years ago would be worth $3,613 today (with dividends reinvested), compared to $109 for SSKN. Over the past 12 months, SBC leads with a +0.3% total return vs SSKN's -93.3%. The 3-year compound annual growth rate (CAGR) favors INMD at -26.4% vs SSKN's -74.5% — a key indicator of consistent wealth creation.

MetricSBC logoSBCSBC Medical Group…SSKN logoSSKNSTRATA Skin Scien…SKIN logoSKINThe Beauty Health…INMD logoINMDInMode Ltd.
YTD ReturnYear-to-date-25.9%-86.2%-35.0%-5.9%
1-Year ReturnPast 12 months+0.3%-93.3%-35.9%-2.1%
3-Year ReturnCumulative with dividends-68.9%-98.3%-91.7%-60.2%
5-Year ReturnCumulative with dividends-67.8%-98.9%-92.9%-63.9%
10-Year ReturnCumulative with dividends-67.8%-99.6%-91.6%+105.0%
CAGR (3Y)Annualised 3-year return-32.2%-74.5%-56.4%-26.4%
INMD leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SSKN and INMD each lead in 1 of 2 comparable metrics.

SSKN is the less volatile stock with a -0.24 beta — it tends to amplify market swings less than SKIN's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INMD currently trades 83.2% from its 52-week high vs SSKN's 4.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSBC logoSBCSBC Medical Group…SSKN logoSSKNSTRATA Skin Scien…SKIN logoSKINThe Beauty Health…INMD logoINMDInMode Ltd.
Beta (5Y)Sensitivity to S&P 5000.76x-0.24x2.00x1.04x
52-Week HighHighest price in past year$5.75$3.86$2.69$16.74
52-Week LowLowest price in past year$2.97$0.11$0.76$12.72
% of 52W HighCurrent price vs 52-week peak+55.8%+4.5%+33.8%+83.2%
RSI (14)Momentum oscillator 0–10029.941.652.139.8
Avg Volume (50D)Average daily shares traded87K14K760K804K
Evenly matched — SSKN and INMD each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: SBC as "Buy", SKIN as "Hold", INMD as "Buy". Consensus price targets imply 180.4% upside for SBC (target: $9) vs 14.9% for INMD (target: $16).

MetricSBC logoSBCSBC Medical Group…SSKN logoSSKNSTRATA Skin Scien…SKIN logoSKINThe Beauty Health…INMD logoINMDInMode Ltd.
Analyst RatingConsensus buy/hold/sellBuyHoldBuy
Price TargetConsensus 12-month target$9.00$1.30$16.00
# AnalystsCovering analysts11311
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+14.5%
Insufficient data to determine a leader in this category.
Key Takeaway

SBC leads in 1 of 6 categories (Profitability & Efficiency). INMD leads in 1 (Total Returns). 3 tied.

Best OverallSBC Medical Group Holdings … (SBC)Leads 1 of 6 categories
Loading custom metrics...

SBC vs SSKN vs SKIN vs INMD: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SBC or SSKN or SKIN or INMD a better buy right now?

For growth investors, SBC Medical Group Holdings Incorporated (SBC) is the stronger pick with 6.

1% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). SBC Medical Group Holdings Incorporated (SBC) offers the better valuation at 6. 7x trailing P/E (7. 1x forward), making it the more compelling value choice. Analysts rate SBC Medical Group Holdings Incorporated (SBC) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SBC or SSKN or SKIN or INMD?

On trailing P/E, SBC Medical Group Holdings Incorporated (SBC) is the cheapest at 6.

7x versus InMode Ltd. at 9. 7x. On forward P/E, SBC Medical Group Holdings Incorporated is actually cheaper at 7. 1x.

03

Which is the better long-term investment — SBC or SSKN or SKIN or INMD?

Over the past 5 years, InMode Ltd.

(INMD) delivered a total return of -63. 9%, compared to -98. 9% for STRATA Skin Sciences, Inc. (SSKN). Over 10 years, the gap is even starker: INMD returned +105. 0% versus SSKN's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SBC or SSKN or SKIN or INMD?

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 24β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately -918% more volatile than SSKN relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — SBC or SSKN or SKIN or INMD?

By revenue growth (latest reported year), SBC Medical Group Holdings Incorporated (SBC) is pulling ahead at 6.

1% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -36. 4% for InMode Ltd.. Over a 3-year CAGR, SSKN leads at 3. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SBC or SSKN or SKIN or INMD?

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus -30. 1% for STRATA Skin Sciences, Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SBC leads at 34. 2% versus -27. 6% for SSKN. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SBC or SSKN or SKIN or INMD more undervalued right now?

On forward earnings alone, SBC Medical Group Holdings Incorporated (SBC) trades at 7.

1x forward P/E versus 9. 6x for InMode Ltd. — 2. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SBC: 180. 4% to $9. 00.

08

Which pays a better dividend — SBC or SSKN or SKIN or INMD?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is SBC or SSKN or SKIN or INMD better for a retirement portfolio?

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 24)). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 6%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SBC and SSKN and SKIN and INMD?

These companies operate in different sectors (SBC (Industrials) and SSKN (Healthcare) and SKIN (Consumer Defensive) and INMD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SBC is a small-cap deep-value stock; SSKN is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; INMD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SBC

Quality Mega-Cap Compounder

  • Sector: Industrials
  • Market Cap > $100B
  • Net Margin > 14%
Run This Screen
Stocks Like

SSKN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 34%
Run This Screen
Stocks Like

SKIN

Quality Business

  • Sector: Consumer Defensive
  • Market Cap > $100B
  • Gross Margin > 38%
Run This Screen
Stocks Like

INMD

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 13%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SBC and SSKN and SKIN and INMD on the metrics below

Revenue Growth>
%
(SBC: -18.3% · SSKN: -21.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.